EQS-News: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) considers strategic options for its Carragelose business and has mandated an external advisor.
- Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) considers strategic options for its Carragelose business and has mandated an external advisor.
- A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners.
- This initiative meets an attractive market environment for those assets that comply with the new EU medical device regulation (MDR).
- Carragelose is a unique, patent-protected, broadly active virus-blocking compound and is currently used in a marketed product portfolio for the prophylaxis and treatment of viral respiratory infections.